GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Liabilities-to-Assets

LakeShore Biopharma Co (LakeShore Biopharma Co) Liabilities-to-Assets : 0.65 (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. LakeShore Biopharma Co's Total Liabilities for the quarter that ended in Sep. 2023 was $144.45 Mil. LakeShore Biopharma Co's Total Assets for the quarter that ended in Sep. 2023 was $220.79 Mil. Therefore, LakeShore Biopharma Co's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 was 0.65.


LakeShore Biopharma Co Liabilities-to-Assets Historical Data

The historical data trend for LakeShore Biopharma Co's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Liabilities-to-Assets Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23
Liabilities-to-Assets
1.44 1.49 0.58

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Liabilities-to-Assets Get a 7-Day Free Trial - 1.49 1.61 0.58 0.65

Competitive Comparison of LakeShore Biopharma Co's Liabilities-to-Assets

For the Biotechnology subindustry, LakeShore Biopharma Co's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LakeShore Biopharma Co's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Liabilities-to-Assets falls into.



LakeShore Biopharma Co Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

LakeShore Biopharma Co's Liabilities-to-Assets Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Liabilities-to-Assets (A: Mar. 2023 )=Total Liabilities/Total Assets
=143.856/249.569
=0.58

LakeShore Biopharma Co's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 is calculated as

Liabilities-to-Assets (Q: Sep. 2023 )=Total Liabilities/Total Assets
=144.451/220.787
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LakeShore Biopharma Co  (NAS:LSB) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


LakeShore Biopharma Co Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.